This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Su-Wen Jiang, Ai-Rong Hu, Yao-Ren Hu, Tao Xiong, Guo-Sheng Gao, Xiao-Yue Liang, Shi-Xiong Ding, Peng-Jian Weng, Institute of Liver Diseases, Ningbo No. 2 Hospital, Ningbo 315010, Zhejiang Province, China
Li-Peng Yao, Ai-Rong Hu, Department of Molecular Biology, School of Medicine, Ningbo University, Ningbo 315010, Zhejiang Province, China
Shi-Xiang Chen, Department of Infectious Diseases, No. 113 Hospital of the PLA, Ningbo 315010, Zhejiang Province, China
Author contributions: Jiang SW, Hu AR and Gao GS participated in research design; Gao GS and Ding SX tested the specimens; Weng PJ tested the specimens and collected the data; Jiang SW, Yao LP, Hu YR, Chen SX, Xiong T and Liang XY collected and analyzed the data; Gao GS analyzed the data and drafted the manuscript; Jiang SW and Hu AR drafted the manuscript.
Supported by BaoenWang Liver Fibrosis Research Fund of the Chinese Foundation for Hepatitis Prevention and Control, No. 20100009; Zhejiang Medicine and Health Sciences Research Fund, No. 2008B167 and No. 2014PYA018; Nanjing Military Area Command of the PLA Medical Technology Innovation, No. 11MA019; Ningbo Health Technology Project for Excellent Young and Middle-aged Talent, No. 2011-145; Ningbo Leader and Top Notch Person Training Project, No. 2012-131; and Zhejiang Medicine and Health Project for Excellent Young Talent, No. 2013-245
Correspondence to: Ai-Rong Hu, MD, Institute of Liver Diseases, Ningbo No. 2 Hospital, 41 Xibei Street, Haishu District, Ningbo 315010, Zhejiang Province, China. huairong6666@126.com
Telephone: +86-574-83870605 Fax: +86-574-83870626
Received: May 28, 2014 Revised: July 17, 2014 Accepted: August 13, 2014 Published online: December 7, 2014
Core Tip
Core tip: Currently, hepatitis B virus (HBV) resistance to adefovir dipivoxil (ADV) has become more prevalent. However, it is not known whether drug-resistant HBV mutants induced by ADV are related to the clinical features of patients. In this study, we analyzed the exhaustive resistant mutants induced by ADV. Of 79 patients, 26 (32.9%) had more than two loci of drug resistance in HBV mutants. Because drug-resistant HBV mutants induced by ADV are complicated and diverse, we conclude that testing for resistant mutants prior to antiviral treatment, administering standard and first-line antiviral treatment, and personalizing medication according to the clinical characteristics of patients is important to avoid subsequent noncompliance and the need for salvage treatment.
